273399-95-4

Basic information

• Product Name: (6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE
• Synonyms: (5-Chloro-1H-benzo[d]iMidazol-2-yl)MethanaMine;[(5-chloro-1H-benzimidazol-2-yl)methyl]amine diHYDROCHLORIDE Salt;(6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE;C-(6-CHLORO-1H-BENZIMIDAZOL-2-YL)-METHYLAMINE;1H-Benzimidazole-2-methanamine,5-chloro-(9CI);1-(6-Chloro-1H-benzimidazol-2-yl)methanamine;[(5-chloro-1H-benzimidazol-2-yl)methyl]amine dihydrochloride;1-(5-chloro-1H-benzimidazol-2-yl)methanamine
• CAS NO: 273399-95-4
• Molecular Formula: C₈H₈ClN₃
• Molecular Weight: 181.62222
• Product Categories: BENZIMIDAZOLE
• Mol File: 273399-95-4.mol

Chemical Properties

• Boiling Point: 417.3 °C at 760 mmHg
• Flash Point: 206.2 °C
• Appearance: /
• Density: 1.429 g/cm³
• Vapor Pressure: 3.58E-07mmHg at 25°C
• Refractive Index: 1.716
• PKA: 11.96±0.29(Predicted)
• CAS DataBase Reference: (6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE(273399-95-4)
• EPA Substance Registry System: (6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE(273399-95-4)

Safety Data

• Hazardous Substances Data: 273399-95-4(Hazardous Substances Data)

Usage

Uses

Due to the limited information provided, specific applications for (6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE are not clearly defined. However, given its structural features and the general properties of benzimidazole compounds, potential uses may include:
Used in Pharmaceutical Industry:
(6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE could be used as a building block or intermediate in the synthesis of pharmaceutical compounds, given the reactivity of its amine and chlorine groups. The benzimidazole core is known to be a versatile scaffold in medicinal chemistry, and the presence of these functional groups may allow for the development of new drugs with specific therapeutic properties.
Used in Chemical Research:
As a member of the benzimidazole class, (6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE may be utilized in chemical research to explore its reactivity, stability, and potential to form new compounds. This could lead to the discovery of novel chemical reactions or the development of new synthetic routes for related compounds.
Used in Material Science:
(6-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)METHANAMINE's structural features and potential reactivity may also make it suitable for use in material science, where it could be explored for its properties in the development of new materials with specific characteristics, such as conductivity, stability, or responsiveness to stimuli.

InChI:InChI=1/C8H8ClN3/c9-5-1-2-6-7(3-5)12-8(4-10)11-6/h1-3H,4,10H2,(H,11,12)

Upstream product

• 1185297-00-0 (5-chloro-1H-1,3-benzodiazol-2-yl)methanamine dihydrochloride salt 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 56-40-6 glycine 
• 4530-20-5 BOC-glycine 
• 712275-17-7 tert-butyl ((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)carbamate 

Downstream Products

• 712275-17-7 tert-butyl ((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)carbamate 
• 713138-80-8 3-chloro-N-(5-chloro-1H-benzoimidazol-2-yl-methyl)-4-methoxycarbonyl-benzamide 

Relevant articles and documents

Synthesis and biological activity of squaramido-tethered bisbenzimidazoles as synthetic anion transporters

A series of squaramido-tethered bisbenzimidazoles were synthesized from the reaction of diethyl squarate with substituted 2-aminomethylbenzimidazoles. These conjugates exhibit moderate binding affinity toward chloride anions. They are able to facilitate the transmembrane transport of chloride anions most probably via an anion exchange process, and tend to be more active at acidic pH than at physiological pH. The viability of these conjugates toward four selected solid tumor cell lines was evaluated using an MTT assay and the results suggest that some of these conjugates exhibit moderate cytotoxicity probably in an apoptotic fashion.

Dibenzimidazole conjugates with pH dependent anion trans-membrane transport activity Synthesis method and synthesis method thereof (by machine translation)

13-bis-benzimidazole conjugate is synthesized by the method, the chloride ion transport activity of each conjugate under the acidic pH condition is higher than the activity at physiological pH, and the synthesized conjugate also shows moderate intensity toxicity on selected solid tumor cells. (by machine translation)

Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer

Casein kinase 1δ/ε have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1δ/ε inhibitors 17 and 28 displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple negative breast cancer cell line and have physical, in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers.

Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds have some common features; three possess 5-halo substituents; two are derivatives of (S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1Hbenzo[ d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be considered promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Synthesis of benzimidazoles from amino acids with solvent-free melting method

By using low cost and readily available amino acids as the synthetic blocks, a series of 2-Aminomethyl-benzimidazole are synthesized with solvent-free melting method. While the condensation of aspartic acid (or asparagine) with o-diaminobenzene gives the

Synthesis and antimicrobial activities of novel peptide deformylase inhibitors

A new series of N-formylhydroxylamine compounds were designed, optimized with the AutoDock 4.0.1to investigate the interactions between the target compounds and the amino acid residues of the Escherichia coli PDF?Ni enzyme, and then synthesized through mu

BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions

The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R1 to R5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties. The compounds of the above general formula I as well as the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, and their stereoisomers have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.